Concepedia

Claudia Martorell

CM

Statistics

Publications

29

Citations

2.3K

H-Index

20

Active since

2004

Affiliations

Bristol-Myers Squibb (United States)(Current)

Gilead Sciences (United States)

Hôpital Cochin

Mercy Medical Center

Orlando Immunology Center

Claudia Martorell is an author at Bristol-Myers Squibb (United States) specializing in pharmacotherapy, pharmacy, and antiviral therapy.

Publications per year

2004–2024

29

Publications

29

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

Anna S. Lok, David Gardiner, Eric Lawitz et al. · New England Journal of Medicine · 2012 · 609 citations · Full text

, , +16

High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients

Michael S. Saag, Rukmini Balu, Elizabeth J. Phillips et al. · Clinical Infectious Diseases · 2008 · 431 citations · Full text

, , +12

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

Stanislas Pol, Reem Ghalib, Vinod K. Rustgi et al. · The Lancet Infectious Diseases · 2012 · 147 citations

, , +12

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Hans‐Jürgen Stellbrink, José Ramón Arribas, Jeffrey L. Stephens et al. · The Lancet HIV · 2019 · 143 citations

, , +16

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

Chloe Orkin, Edwin DeJesus, Paul E. Sax et al. · The Lancet HIV · 2020 · 136 citations · Full text

, , +17

1–5 of 29